Skip to content

Tranexamic acid combined with transdermal absorption technique for the treatment of melasma: a randomized controlled trial

Tranexamic acid combined with transdermal absorption technique for the treatment of melasma: a randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024257
Enrollment
Unknown
Registered
2019-07-03
Start date
2019-07-05
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma

Interventions

Control group:Simple hydrating mask
Experimental group:tranexamic acid combined with transdermal absorption technology mask

Sponsors

Department of Plastic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Adults between the ages of 18 and 60 years; 2) diagnosed as chloasma; 3) no contraindications to tranexamic acid; 4) voluntarily participate in the study and voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Pregnant women, lactating women or women who have a pregnancy plan within six months after the end of the study; 2) Women with long-term oral contraceptives; 3) Facial combined with other pigmented abnormal diseases (such as ankle brown cyanosis, vitiligo, Riehl melanosis, etc.); 4) The treatment area has serious diseases such as hemorrhoids, eczema, allergic dermatitis, or scars and excessive hair that have obvious effects on the observation; 5) Participate in other facial cosmetic clinical studies during the study period; 6) Reluctant to stop all whitening cosmetics and take sunscreen measures during the study period; 7) History of systemic systemic diseases (history of thyroid, liver, cardiovascular disease, dyslipidemia, anemia, abnormal blood coagulation mechanism, combined with infectious diseases, psoriasis, diabetes, etc.); 8) Those who have experienced exposure within 1 month before the start of the study; 9) Received any treatment for chloasma (resurfacing, laser, intense pulsed light, drugs, etc.) within 6 months prior to the start of the study.

Design outcomes

Primary

MeasureTime frame
the modified melasma area and severity index (mMASI);

Secondary

MeasureTime frame
satisfaction questionnaire;

Countries

China

Contacts

Public ContactMin Yao

Department of Plastic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

18372501721@163.com+86 13803510718

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026